Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma

Affiliations

• ¹ Global Medical, Global Specialty and Primary Care, GSK House, Brentford, Middlesex, UK.
• ² Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
• ³ CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
• ⁴ Section of Cardiorespiratory and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
• ⁵ S. Anna University Hospital, Ferrara, Italy.
• ⁶ Harvard Medical School and Asthma Research Center, Brigham and Women's Hospital, Boston, MA, USA.
• ⁷ Biostatistics, GSK, Uxbridge, UK.
• ⁸ Respiratory Discovery Medicine, GSK, Stevenage, UK.
• ⁹ Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.
• ¹⁰ Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA.
• ¹¹ Respiratory Medical Franchise, GSK, London, UK.